Want to see JP:4563 full AI Analyst Report?
Top Page
AnGes
(4563)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥35.00
▼(-12.50% Downside)
Action:Reiterated
Date:09/12/26
The score is primarily weighed down by weak financial performance driven by persistent losses and heavy cash burn despite improving revenue momentum. Technicals add further pressure with a clear downtrend below key moving averages, partially offset by oversold readings. Valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Accelerating Revenue Growth
The acceleration in revenue indicates improving commercial traction for AnGes’s biotechnology activities and suggests that products, partnerships, or development-related income are gaining scale. If sustained, stronger top-line growth can provide a broader base for future operating leverage and investment in the pipeline.
Negative Factors
Persistent Operating Losses
Continued operating and net losses show that revenue growth has not yet translated into a self-sustaining earnings model. Persistent unprofitability can constrain internal investment capacity, increase dependence on future financing or partnerships, and make the durability of the business model dependent on successful commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
The acceleration in revenue indicates improving commercial traction for AnGes’s biotechnology activities and suggests that products, partnerships, or development-related income are gaining scale. If sustained, stronger top-line growth can provide a broader base for future operating leverage and investment in the pipeline.
Read all positive factors
AnGes (4563) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥14.36B
Dividend YieldN/A
Average Volume (3M)1.94M
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth35.28%
EPS Growth90.12%
CountryJP
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-9.53
Shares Outstanding398,835,540
10 Day Avg. Volume1,824,910
30 Day Avg. Volume1,941,360
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)7.04
Price to Sales (P/S)24.76
P/FCF Ratio-3.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AnGes Business Overview & Revenue Model
Company Description
AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor (HGF) Pla...
How the Company Makes Money
AnGes primarily makes money by monetizing its biotechnology pipeline and approved products through a combination of product-related revenue and collaboration-based income. Revenue can include (1) sales of any commercialized products the company ha...
AnGes Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 961.90M | 874.12M | 643.00M | 152.99M | 67.06M | 64.15M |
| Gross Profit | 398.00M | 320.38M | 247.00M | 19.45M | -26.83M | 7.43M |
| EBITDA | -5.51B | -5.09B | -5.74B | -8.86B | -13.41B | -13.21B |
| Net Income | -3.87B | -5.12B | -28.13B | -7.44B | -14.71B | -13.68B |
Balance Sheet | ||||||
| Total Assets | 3.66B | 5.41B | 4.67B | 28.89B | 38.82B | 45.46B |
| Cash, Cash Equivalents and Short-Term Investments | 296.72M | 1.88B | 1.71B | 4.16B | 11.04B | 17.90B |
| Total Debt | 723.78M | 54.37M | 272.45M | 362.68M | 1.16B | 0.00 |
| Total Liabilities | 3.45B | 2.33B | 2.51B | 2.79B | 8.40B | 6.82B |
| Stockholders Equity | 205.68M | 3.08B | 2.16B | 26.10B | 30.43B | 38.63B |
Cash Flow | ||||||
| Free Cash Flow | -1.38B | -5.76B | -6.69B | -8.84B | -11.23B | -11.46B |
| Operating Cash Flow | -1.38B | -5.75B | -6.61B | -8.74B | -11.21B | -11.38B |
| Investing Cash Flow | -80.00K | 18.48M | -130.80M | -356.65M | -97.14M | -154.87M |
| Financing Cash Flow | 567.54M | 5.90B | 4.20B | 2.04B | 3.57B | 17.38B |
AnGes Technical Analysis
Negative
40.00
Price Trends
43.80
Negative
46.26
Negative
53.13
Negative
Market Momentum
-2.34
Positive
31.32
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4563, the sentiment is Negative. The current price of 40 is above the 20-day moving average (MA) of 38.00, below the 50-day MA of 43.80, and below the 200-day MA of 53.13, indicating a bearish trend. The MACD of -2.34 indicates Positive momentum. The RSI at 31.32 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4563.
AnGes Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥120.31B | -15.04 | -12.23% | 0.33% | 7.12% | -137.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥199.54B | -123.18 | ― | ― | 1662.38% | 42.86% | |
47 Neutral | ¥41.21B | 61.29 | ― | ― | -47.32% | ― | |
46 Neutral | ¥34.44B | -78.23 | ― | ― | 3.43% | -53.59% | |
43 Neutral | ¥14.36B | -3.78 | -163.39% | ― | 35.28% | 90.12% |
* Healthcare Sector Average
JP:4563
AnGes
36.00
-47.00
-56.63%
JP:4565
Sosei Group
1,299.00
287.00
28.36%
JP:4588
Oncolys BioPharma, Inc.
6,770.00
6,135.00
966.14%
JP:4593
Healios KK
304.00
-318.00
-51.13%
JP:7774
Japan Tissue Engineering Co., Ltd.
848.00
334.00
64.98%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.